The delayed start to deliveries of the J&J vaccine is yet another blow to the rollout in continental Europe and on its own could delay things by at least one month compared to a situation in which the recent pace of vaccinations is sustained. Strategists at Capital Economics answer five key questions about the latest obstacle.
Yet another setback to Europe’s vaccination campaign
“What’s the issue with the J&J jab? There have been reports of ‘rare and severe’ blood clots in the US amongst the people who have received the J&J vaccine, all in women between the ages of 18 and 48.”
“What does it mean? US authorities have recommended suspending usage of the J&J vaccine for now, and the company has delayed deliveries in Europe, which were scheduled to start today. Note that the vaccine was authorised by the European regulator in March. The EMA has said that there is not a clear causal link between the vaccine and the incidents in the US, but it is currently reviewing the US data.”
“How big a deal is this for Europe’s vaccine rollout? It is incredibly unhelpful, to say the least. Just as the pace of vaccinations in Europe was gathering pace, this is the last thing that the rollout needed.
“How about vaccine hesitancy? The issue seems likely to hit confidence in the J&J jab itself. Admittedly, polls indicate that this has not affected confidence in the mRNA-based jabs as much, and it is possible that there is little blowback this time too given that the rare blood clot side-effect seems to be associated with the ‘viral vector’ vaccines. However, even if this proves the case, it would only increase the reliance on the Pfizer jab in the EU and leave the rollout exposed to any potential issues with that jab which may yet arise.”
“What does this mean for the easing of restrictions? It is hard to say with any degree of certainty, but it is likely to make it difficult to sustain the recent pace of vaccinations. While it is not our baseline assumption, if neither the J&J nor AstraZeneca jabs end up being used, this could delay the vaccination programme by at least two months. We are sticking to our assumption that the euro-zone countries will vaccinate 50% of adults by mid-July, which should allow for a substantial easing of restrictions in Q3. However, any upside risks to this are shrinking fast.”
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD extends gains above 1.0700, focus on key US data
EUR/USD meets fresh demand and rises toward 1.0750 in the European session on Thursday. Renewed US Dollar weakness offsets the risk-off market environment, supporting the pair ahead of the key US GDP and PCE inflation data.
GBP/USD extends recovery above 1.2500, awaits US GDP data
GBP/USD is catching a fresh bid wave, rising above 1.2500 in European trading on Thursday. The US Dollar resumes its corrective downside, as traders resort to repositioning ahead of the high-impact US advance GDP data for the first quarter.
Gold price edges higher amid weaker USD and softer risk tone, focus remains on US GDP
Gold price (XAU/USD) attracts some dip-buying in the vicinity of the $2,300 mark on Thursday and for now, seems to have snapped a three-day losing streak, though the upside potential seems limited.
Injective price weakness persists despite over 5.9 million INJ tokens burned
Injective price is trading with a bearish bias, stuck in the lower section of the market range. The bearish outlook abounds despite the network's deflationary efforts to pump the price.
US Q1 GDP Preview: Economic growth set to remain firm in, albeit easing from Q4
The United States Gross Domestic Product (GDP) is seen expanding at an annualized rate of 2.5% in Q1. The current resilience of the US economy bolsters the case for a soft landing.